Origin and Chemical Structure
Lovastatin is a natural statin isolated from the fungal culture Aspergillus terreus. It subsequently served as the chemical template for developing semi-synthetic analogs (simvastatin and pravastatin).
The drug's structure strictly dictates its pharmacological activity (SAR):
- Hydronaphthalene ring — A key element ensuring binding to the enzyme HMG-CoA reductase.
- Side chain (represented by a hydroxy acid) — Grants the molecule a structural resemblance to mevalonate, the natural substrate for this enzyme.
Mechanism of Action
Pharmacologically, lovastatin is a prodrug. In the tablet, it exists as an inactive lactone. Upon entering the body, the drug undergoes hydrolysis to convert into the pharmacologically active $\beta$-hydroxy acid.
Inhibition of cholesterol synthesis occurs strictly inside hepatocytes. For the drug to reach its target, the hepatic transporter OATP1B1 is required. It ensures active uptake of the statin from the blood into the liver during first-pass metabolism. The function of this transporter serves a dual purpose:
- Therapeutic: delivering the drug directly to the site of action to ensure efficacy.
- Toxicological: sharply decreasing the drug concentration in the systemic circulation, preventing systemic adverse effects (primarily myopathy).
Pharmacokinetics
Upon oral administration, the bioavailability of lovastatin is extremely low (less than 5% — the lowest among the statin class). This is due to pronounced presystemic metabolism in the liver (first-pass effect).
- Effect of food: Unlike pravastatin and fluvastatin, the bioavailability of lovastatin increases when taken with a meal.
- Time parameters: Maximum plasma concentration ($T_{max}$) is reached slowly — in 2 to 4 hours.
- Distribution: The drug is highly lipophilic, allowing it to readily cross blood-tissue barriers, including the blood-brain barrier (BBB) and the placenta.
Drug Interactions (CYP3A4)
Lovastatin is metabolized by the most extensive cytochrome P450 isoenzyme group — CYP3A4 / CYP3A5. This requires careful evaluation of concurrent therapy, as alterations in enzyme activity directly affect treatment safety.
- CYP3A4 inhibitors slow down the breakdown of the statin. This leads to drug accumulation in the blood and a sharp increase in the risk of myopathy. Strong inhibitors include: azole antifungals (ketoconazole), macrolides (erythromycin, clarithromycin), cardiovascular drugs (verapamil, diltiazem, quinidine), antivirals (ritonavir), as well as dietary components such as furanocoumarins in grapefruit juice.
- CYP3A4 inducers accelerate drug elimination, reducing its therapeutic efficacy. These include: anticonvulsants (carbamazepine, phenytoin, barbiturates), the antibiotic rifampin, glucocorticoids, and herbal products (St. John's wort, containing hyperforin).
Prescribing and Administration
The drug is administered orally. The standard therapeutic dosage range is 20–40 mg daily.
Example of a prescription for 20 mg tablets:
Rp.: Tab. Lovastatini 0.02 D.t.d. N. 30 S. Take orally, 1 tablet once daily (after meals).